Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
54M
-
Shares change
-
-546K
-
Total reported value, excl. options
-
$169M
-
Value change
-
+$2.66M
-
Put/Call ratio
-
0.44
-
Number of buys
-
61
-
Number of sells
-
-34
-
Price
-
$3.12
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q2 2018
112 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2018.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54M shares
of 123M outstanding shares and own 43.82% of the company stock.
Largest 10 shareholders include Broadfin Capital, LLC (6.77M shares), BlackRock Inc. (6.06M shares), Consonance Capital Management LP (6.04M shares), venBio Select Advisor LLC (4.5M shares), VANGUARD GROUP INC (4.27M shares), BAKER BROS. ADVISORS LP (3.62M shares), MORGAN STANLEY (1.74M shares), ARMISTICE CAPITAL, LLC (1.7M shares), MANGROVE PARTNERS (1.68M shares), and MILLENNIUM MANAGEMENT LLC (1.61M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.